  The emergence of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As
no specific therapeutics are yet available to control disease evolution, more
in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will
help to characterize new targets for the management of COVID-19. The present
study identified a specific set of biological pathways altered in primary human
lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from
the 2003 pandemic was studied. The transcriptomic profiles were also exploited
as possible novel therapeutic targets, and anti-signature perturbation analysis
predicted potential drugs to control disease progression. Among them,
Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT),
mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors
emerged as candidate drugs. Finally, sex-specific differences that may underlie
the higher COVID-19 mortality in men are proposed.
